Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411311 | 0.87 | NT5E (0.36) | NT5EALDH1A1ABCB1L3MBTL1BCHE | |
| SCHEMBL15481395 | 0.85 | L3MBTL1 (0.39) | NT5EALDH1A1L3MBTL1 | |
| SCHEMBL11981188 | 0.84 | BCHE (0.40) | NT5EL3MBTL1BCHE | |
| SCHEMBL10148633 | 0.83 | L3MBTL1 (0.38) | L3MBTL1BCHETMEM97SIGMAR1 | |
| SCHEMBL12411310 | 0.83 | NT5E (0.37) | NT5EALDH1A1ABCB1L3MBTL1BCHE | |
| SCHEMBL3856812 | 0.79 | ALDH1A1 (0.46) | NT5EALDH1A1L3MBTL1BCHE | |
| SCHEMBL7691337 | 0.78 | ALDH1A1 (0.55) | ALDH1A1ABCB1 | |
| SCHEMBL17773534 | 0.78 | PTGES2 (0.41) | ALDH1A1ABCB1BCHE | |
| SCHEMBL16378350 | 0.78 | ALDH1A1 (0.37) | NT5EALDH1A1ABCB1BCHE | |
| SCHEMBL14362931 | 0.78 | METAP2 (0.37) | L3MBTL1BCHETMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114970-B2 | Synthetic heparin monosaccharides | ALCHEMIA LIMITED (AU) | 2012-02-14 | — | — | US | disclosed |
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | ALCHEMIA LIMITED (AU) | 2009-07-23 | — | — | US | disclosed |
| US-7541445-B2 | Synthetic heparin pentasaccharides | ALCHEMIA LIMITED (AU) | 2009-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187013-A1 | SYNTHETIC HEPARIN PENTASACCHARIDES | HPSE, DDOST, STT3A | NT5E 1426/4885ALDH1A1 4671/4885ABCB1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.